Results 31 to 40 of about 2,475,393 (270)

Identification of novel human dipeptidyl peptidase-IV inhibitors of natural origin (Part II): in silico prediction in antidiabetic extracts. [PDF]

PLoS ONE, 2012
BACKGROUND: Natural extracts play an important role in traditional medicines for the treatment of diabetes mellitus and are also an essential resource for new drug discovery.
Laura Guasch, Esther Sala, María José Ojeda, Cristina Valls, Cinta Bladé, Miquel Mulero, Mayte Blay, Anna Ardévol, Santiago Garcia-Vallvé, Gerard Pujadas   +9 more
doaj   +1 more source

Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection

Pharmaceuticals, 2021
The current outbreak of severe acute respiratory distress syndrome (SARS) or nCOVID-19 pandemic, caused by the coronavirus-2 (CoV-2), continues to wreak havoc globally.
Praveen P. N. Rao, Amy Trinh Pham, Arash Shakeri, Amna El Shatshat, Yusheng Zhao, Rahul C. Karuturi, Ahmed A. Hefny   +6 more
doaj   +1 more source

Synthetic Approaches to Novel DPP-IV Inhibitors—A Literature Review

Molecules
Dipeptidyl peptidase IV (DPP-IV) is a serine protease whose inhibition has been an object of considerable interest in the context of developing novel treatments for type 2 diabetes mellitus.
Valentin Petrov, Teodora Aleksandrova, Aleksandar Pashev   +2 more
doaj   +1 more source

Metabolic Syndrome-Preventive Peptides Derived from Milk Proteins and Their Presence in Cheeses: A Review

Applied Sciences, 2020
The metabolic syndrome (MetS) is defined as the occurrence of diet-related diseases such as abdominal obesity, atherogenic dyslipidemia, hyperglycemia (insulin resistance) and hypertension.
Anna Iwaniak, Damir Mogut
doaj   +1 more source

A thin-layer chromatography-bioautographic method for detecting dipeptidyl peptidase IV inhibitors in plants

, 2015
A thin-layer chromatography (TLC)-bioautographic method was developed with the aim to detect dipeptidyl peptidase IV (DPP IV) inhibitors from plant extracts.
Wang, C.-H., Gu, L.-H., Hu, H.J., Chou, G.-X., Bligh, S.W.A., Wang, Z.T., Liao, L.P.   +6 more
core   +1 more source

Inhibition of dipeptidyl peptidase 7 impairs lysophagy in LLOMe‐treated HepG2 cells

FEBS Letters, EarlyView.
DPP7 inhibition delays ubiquitin‐dependent lysophagy by attenuating ubiquitin accumulation and the recruitment of SQSTM1 and LC3 to damaged lysosomes, resulting in delayed clearance of damaged lysosomes and impaired restoration of lysosomal homeostasis. Created using FigureLabs (Certificate ID: FL‐PUB‐20260922‐Z99XNX).
Na Yeon Park, Inho Kwon, Yong Hwan Kim, Ji‐Eun Bae, Joon Bum Kim, Seong Hyun Kim, Sungho Maeng, Doo Sin Jo, Dong‐Hyung Cho   +8 more
wiley   +1 more source

Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus [PDF]

Diabetes & Metabolism Journal, 2016
Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral antidiabetic agent for the treatment of type 2 diabetes mellitus. They increase endogenous levels of incretin hormones, which stimulate glucose-dependent insulin secretion, decrease ...
Sung-Ho Kim, Jung-Hwa Yoo, Woo Je Lee, Cheol-Young Park   +3 more
doaj   +1 more source

Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes

, 2022
The effects of sodium-glucose cotransporter 2 inhibitors (SGLT2I) vs dipeptidyl peptidase-4 inhibitors (DPP4I) on the risk of new-onset gout remains unknown. This study aims to compare the effects of SGLT2I against DPP4I on gout risks.
Li, Lifang, Tse, Gary, Liu, Xuejin, Jing, Fengshi, Cheung, Bernard Man Yung, Wong, Wing Tak, Zhang, Qingpeng, Chou, Oscar Hou-In, Liu, Tong, Chang, Carlin, Lee, Sharen, Zhou, Jiandong   +11 more
core   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley   +1 more source

Fast Skeletal Muscle Troponin and Tropomyosin as a Dietary Source of Antidiabetic and Antihypertensive Bioactive Peptides: An In Silico Study

Vitae, 2023
Background : The nutraceutical properties of food hydrolysates rely on multiple biochemical interactions involving the modulation of enzymes and cellular receptors.
Jorge Andrés Barrero, María Alejandra Barrero, Angélica María González Clavijo, Claudia Marcela Cruz   +3 more
doaj   +1 more source